Communiqués Portage Biotech Inc.

Actions

PRTG

VGG7185A1286

Temps réel estimé Cboe BZX Autres places de cotation 18:17:12 28/06/2024			Varia. 5j.	Varia. 1 janv.
0,255 ^USD	+12,83%		+10,78%	-85,21%

03/06	Wall Street s'apprête à ouvrir en légère hausse lundi, les investisseurs attendant les principales données manufacturières pour le mois de mai	MT
03/06	Les investisseurs attendent les données clés de l'industrie manufacturière et les contrats à terme américains sont en hausse dans la séance de pré-marché de lundi.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Portage Biotech : Director Resignations - Form 6-K	02/05	PU
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused	15/04	AQ
Portage biotech announces plans to expand its evaluation of strategic alternatives	15/04	AQ
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives	12/04	AQ
Portage biotech completes monetization of intensity therapeutics shares	27/03	AQ
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares	26/03	AQ
Portage Biotech : Corporate Presentation - March 2024	07/03	PU
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update	28/02	AQ
Portage Biotech Reports Business and Strategic Update	04/01	AQ
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update	28/11	AQ
Portage biotech presents updates on its inkt and adenosine programs at the society for immunotherapy of cancer's 38th annual meeting	07/11	AQ
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	06/11	AQ
Portage biotech announces $6.0 million registered direct offering	02/10/23	AQ
Portage Biotech Announces $6.0 Million Registered Direct Offering	29/09/23	AQ
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference	20/09/23	AQ
Portage Biotech : Corporate Presentation - September 2023	08/09/23	PU
Portage biotech announces collaboration with merck to evaluate two next-generation adenosine antagonists in combination with keytruda in solid tumors	06/09/23	AQ
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors	05/09/23	AQ
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update	30/08/23	AQ
Portage Biotech : NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS - Form 6-K	29/08/23	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Portage Biotech Inc.

Actions

PRTG

VGG7185A1286

Communiqués

Filtres